InspireMD, Inc. (NSPR)

NASDAQ: NSPR · IEX Real-Time Price · USD
3.20
-0.15 (-4.48%)
At close: Sep 27, 2023, 4:00 PM
3.17
-0.03 (-0.94%)
After-hours: Sep 27, 2023, 6:00 PM EDT
-4.48%
Market Cap 67.82M
Revenue (ttm) 5.35M
Net Income (ttm) -18.71M
Shares Out 21.20M
EPS (ttm) -1.95
PE Ratio n/a
Forward PE 11.70
Dividend n/a
Ex-Dividend Date n/a
Volume 25,384
Open 3.26
Previous Close 3.35
Day's Range 3.19 - 3.45
52-Week Range 0.81 - 3.77
Beta 1.00
Analysts Strong Buy
Price Target 3.88 (+21.25%)
Earnings Date Nov 7, 2023

About NSPR

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Marvin L. Slosman
Employees 55
Stock Exchange NASDAQ
Ticker Symbol NSPR
Full Company Profile

Financial Performance

In 2022, InspireMD's revenue was $5.17 million, an increase of 15.04% compared to the previous year's $4.50 million. Losses were -$18.49 million, 24.0% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for NSPR stock is "Strong Buy." The 12-month stock price forecast is $3.88, which is an increase of 21.25% from the latest price.

Price Target
$3.88
(21.25% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

TEL AVIV, Israel, and MIAMI, Aug. 31, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announ...

27 days ago - GlobeNewsWire

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and seco...

7 weeks ago - GlobeNewsWire

InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Sten...

2 months ago - GlobeNewsWire

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform Company...

3 months ago - GlobeNewsWire

InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announce...

4 months ago - GlobeNewsWire

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront -

4 months ago - GlobeNewsWire

InspireMD Announces Private Placement of Up to $113.6 Million

Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members

4 months ago - GlobeNewsWire

InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast

- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System ...

4 months ago - GlobeNewsWire

InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (E...

5 months ago - GlobeNewsWire

InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform

Procedure performed as part of the company's ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system

5 months ago - GlobeNewsWire

InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update

TEL AVIV, Israel, April 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease a...

5 months ago - GlobeNewsWire

InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

- 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 -

6 months ago - GlobeNewsWire

InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer

Mr. Tommasoli formerly served as the Company's Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. J...

6 months ago - GlobeNewsWire

InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update

-Conference call and webcast to be held at 8:30 a.m. EDT-

7 months ago - GlobeNewsWire

InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing

Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing Seasoned veteran in vascular space adds significant expertise in U.S. c...

8 months ago - GlobeNewsWire

InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium

TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the comp...

11 months ago - GlobeNewsWire

InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update

- Generated 38.8% growth in CGuard™ revenue year-over-year -

11 months ago - GlobeNewsWire

InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update

-Conference call and webcast to be held at 8:30 a.m. EDT- -Conference call and webcast to be held at 8:30 a.m. EDT-

1 year ago - GlobeNewsWire

InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference

TEL AVIV, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the com...

1 year ago - GlobeNewsWire

NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development

TOLEDO, Ohio & TEL AVIV, Israel--(BUSINESS WIRE)-- #CRO--NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (Nasda...

1 year ago - Business Wire

InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

- Generated 47.8% growth in CGuard™ revenue year-over-year -

1 year ago - GlobeNewsWire

InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update

- Conference call and webcast to be held at 8:30 a.m. EDT -

1 year ago - GlobeNewsWire

InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

Credited with performing the first ever endovascular repair procedure in 1990 Credited with performing the first ever endovascular repair procedure in 1990

1 year ago - GlobeNewsWire

InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022

Successful live case transmission again demonstrated CGuard's™ differentiated patient protection features and ease of use Successful live case transmission again demonstrated CGuard's™ differentiated ...

1 year ago - GlobeNewsWire

5 Stocks To Watch For June 6, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Science Applications International Corporation (NYSE: SAIC) to report quarterly earnings at $1.77 per share on revenue of...

Other symbols: COUPHQYOPSAIC
1 year ago - Benzinga